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Abstract
Objective: To compare the success rate of external cephalic
version (ECV) at term using ritodrine or atosiban as a toco-
lytic agent.
Study design: Prospective cohort study with a sample of 236
pregnant women with a breech presentation at term, from
November 2006 to March 2008. Data have been analyzed
from the moment the cephalic version is performed until the
time of delivery.
Results: ECV success rate using ritodrine as a tocolytic
agent was 56.8% compared to 31.4% with atosiban. Rito-
drine increases the version success potential more signifi-
cantly than atosiban (P-0.05). In both cases, the use of ECV
reduced the rate of cesarean sections, although a higher num-
ber of versions are required with atosiban wnumbers needed
to treat (NNT)s9.08x to avoid a cesarean section compared
to ritodrine (NNTs3.41).
Conclusions: Ritodrine seems better than atosiban as toco-
lytic agent for ECVs.
Keywords: Breech presentation; external cephalic version
(ECV); ritodrine; tocolityc agents; vasotocin.
Introduction
Breech presentation occurs in 3–4% of gestations at term.
The preferred mode of delivery has changed throughout the
years and after the publication of the term breech trial w17x,
the preferred option has been to perform elective cesarean
sections with the aim of reducing perinatal morbidity and
mortality at the cost of increasing the cesarean section rate
and thus, maternal morbidity and mortality.
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External cephalic version (ECV) is a procedure used to
rotate the fetal presenting part from breech to cephalic
through a series of external maneuvers. This procedure,
which has been known for many years now, has received
much attention in recent times because it reduces breech
presentation at delivery and consequently the rate of cesarean
sections. For this very reason, the major scientific societies
w3, 16, 23x recommend the use of this procedure in routine
clinical practice.
A review w2x reports that tocolysis during the procedure
increases the success rate of cephalic versions at term, beta-
mimetics being the most widely studied drugs. More recently,
modern drugs have shown tocolytic efficacy in premature
labor with fewer side effects. Based on the low rate of side
effects, selective antagonists of oxytocin (i.e., atosiban) are
currently the preferred option. The purpose of this study is
to compare the success rate of ECV at term using ritodrine
or atosiban as tocolytic agent.
Materials and methods
A prospective cohort study was performed between November 2006
and March 2008 at our hospital. This procedure was offered to all
patients with singleton breech-presenting gestations at term, provid-
ed there were no contraindications. Exclusion criteria to the use of
ECV in our hospital include placenta previa, premature placental
abruption, oligohydramnios wamniotic fluid index (AFI) -5x, signs
of fetal compromise, fetal death, severe malformations, multiples,
isoimmunization, coagulation disorders and indication of cesarean
section not related to fetal presentation.
All patients were informed in detail about the procedure, explain-
ing the benefits and risks. Upon admission, before the procedure,
an obstetric ultrasound is performed to confirm presentation on the
day of the ECV and to determine fetal weight and placental location,
breech variety and amount of amniotic fluid. Prior to ECV, a car-
diotocography (CTG) was performed for 20 min to confirm fetal
well-being. The technique is performed in the delivery unit, on an
empty stomach, under tocolysis and with ultrasonographic and CTG
supervision. Anesthesia and immediate operative facilities were
available in case an emergency cesarean section was required. Our
hospital’s protocol approved the use of either one of these tocolytics,
except in the case of patients with contraindications to the use of
betamimetics, which does not apply to any of the patients of the
cohorts. Ritodrine (Prepar, Laboratorios Reig Jofre SA, Spain) was
administered via continuous 200 mg infusion pump starting 30 min
before the version and is maintained during the maneuver; and ato-
siban (Tractocile, Laboratorios Ferring SA, Spain) is administered
intravenously in a single 0.9 mL bolus only 2 min before the tech-
nique is applied. The ECVs were always performed by the same
two obstetricians.
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Table 1 Clinical and demographics characteristics of the study population.
Atosiban (ns118) Ritodrine (ns118) P-value
Age of women 32.20"4.30 32.48"4.35 0.99
Parity
Nulliparous 84 (71.2%) 83 (70.9%) 0.96
Parous-1 30 (25.4%) 31 (26.5%)
Parous-2q 4 (3.4%) 3 (2.6%)
Previous cesarean section 4 (3.4%) 5 (4.3%)
Weeks in ECV
37 weeks 97 (82.2%) 95 (81.2%) 0.44
38 weeks 16 (13.6%) 13 (11.1%)
39 weeks 5 (4.2%) 7 (6%)
40 weeks 0 (0%) 2 (1.7%)
Missing 1
Placental location
Anterior 40 (33.9%) 39 (33.3%) 0.99
Posterior 65 (55.1%) 62 (53%)
Fundal – lateral 13 (11%) 12 (10.2%)
Missing 5
Breech variety
Frank 79 (66.9%) 70 (59.8%) 0.12
Complete – double footling 28 (23.7%) 40 (34.2%)
Incomplete 11 (9.4%) 6 (5.1%)
Missing 2
Amount of fluid
Normal 111 (94.1%) 105 (89.7%) 0.15
Scarce (AFI 5–8) 6 (5.1%) 6 (5.1%)
Abundant 1 (0.8%) 6 (5.1%)
Missing 1
Estimated fetal weight (g) 2.939"331 2.948"357 0.84
Values are presented as n (%) and mean"standard deviation (SD).
ECVsexternal cephalic version; AFIsamniotic fluid index.
After the version attempt, a continuous CTG is done during a
total of 60 min to verify fetal status and the presence of side effect
in patients. Anti-D was also administered if indicated. If no further
complications arise, the patient is discharged. The procedure is con-
sidered to be successful if there is a rotation from breech to cephalic
presentation. Subsequently, patients are monitored until the moment
of delivery by examining obstetric variables (i.e., presentation at
delivery, incidence of cesarean section, instrumental delivery rate)
as well as perinatal results (incidence of neonatal Apgar scores -7
at 5 min, mean cord arterial pH, neonatal intensive cares unit admis-
sion rate).
The two obstetricians who perform the versions are the ones to
decide which drug shall be used. Data regarding all versions per-
formed until March 2008 (ns320) were collected since November
2006. In March 2008, the cases belonging to each cohort were
defined by means of a computer-based allocation of the total number
of versions performed. The analysis yielded a 1:1 ratio and similar
rates of the factors associated with the success (i.e., parity, previous
cesarean section, gestational weeks, breech type, placental location,
amniotic fluid and estimated fetal weight).
To detect a 20% difference in the success rate against our baseline
success rate, which was 55%, with a power of 80% (as0.05), a
minimum of 110 women are needed in each group. A total of 118
cases were finally selected in each cohort (ns236). Dichotomous
data were evaluated by the Pearson’s x2-test and continuous data
were analyzed by Student’s t-test. The statistical analysis has been
applied with the SPSS v15 program. Significance was set at a
P-0.05.
Results
Table 1 shows the characteristics of the two cohorts, each
comprising 118 patients. Both cohorts were relatively
homogenous in nature, i.e., similar parity, placental location
and breech type. Follow-up was available on all women.
In the atosiban cohort, breech presentation was modified
to cephalic presentation in a total of 37 patients (31.4% suc-
cess rate) as opposed to 67 patients in the ritodrine cohort
(56.8% success rate, P-0.05).
Five complications have been registered after the use of
ECV, all of which occurred with ritodrine. There were three
episodes of vaginal hemorrhage (two after an unsuccessful
attempt and one after a successful version), which is why a
cesarean section was finally performed in these three cases.
In another patient, a non-reassuring cardiotocographic trac-
ing was detected after a successful cephalic version. It was
then decided to terminate pregnancy via induction and the
delivery ended with a cesarean section by secondary arrest
of dilatation due to fetal malposition with a good perinatal
outcome. None of the four infants had to be transferred to
the neonatal unit and all were discharged without further
complications. Lastly, another patient showed signs of dysp-
nea, dizziness and perspiration after the ritodrine infusion.
The chest X-ray showed signs compatible with acute pul-
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Figure 1 Evolution from atosiban cohort from ECV to delivery.
Values are presented as n (%); ECVsexternal cephalic version.
monary edema. The patient improved after treatment with
furosemide and potassium. After a eutocic vaginal delivery
with cephalic presentation, the newborn was admitted to the
neonatal unit due to upper and lower limb deformity with
ankylosis and was then discharged with a sensory-motor
myelinizing polyneuropathy.
Figures 1 and 2 show the outcomes of both groups from
the moment the version is performed until the time of deliv-
ery. As indicated, the fetal presentation rate remained con-
stant from the version to the time of labor, including
spontaneous reversions to breech presentation as well as the
spontaneous versions to cephalic position. The cesarean sec-
tion rate with ritodrine was 36.4%, compared to 57.6% with
atosiban, P-0.05.
The number of versions that had to be performed in our
hospital with ritodrine in order to avoid breech presentation
at labor was 1.84 (95% CI 1.57–2.23) as compared to 3.37
(95% CI 2.59–4.82) with atosiban. Moreover, a total of 9.08
versions (95% CI 4.30–82.45) were required with atosiban
in order to avoid cesarean sections, as compared to 3.41
(95% CI 2.49–5.41) with ritodrine.
Perinatal results are shown in Table 2. No significant dif-
ferences were identified with regards to the 5-min Apgar
scores -7, umbilical cord pH -7.10 and neonatal admission
rate. No complication was observed in infants associated
with ECV.
Discussion
The use of ECV is an efficient way of reducing breech pres-
entations at delivery as well as the cesarean section rate in
this group of patients. A recent Cochrane review w2x con-
cludes that tocolysis during the procedure increases the suc-
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Figure 2 Evolution from ritodrine cohort from ECV to delivery.
Values are presented as n (%); ECVsexternal cephalic version.
Table 2 Perinatal results.
Atosiban Ritodrine P-value
Apgar -7 at 5 min 2 (1.7%) 2 (1.7%) NS
Mean cord arterial pH -7.10 5 (4.3%) 4 (3.4%) NS
Neonatal intensive care unit admission rate 5 (4.3%) 4 (3.4%) NS
Values are presented as n (%).
NSsno significance.
cess rate of cephalic versions at term. The purpose of this
study is to compare the success rate of ECV at term using
ritodrine or atosiban as tocolytic agent.
The characteristics of both cohorts in our study, as speci-
fied in Table 1, are very similar to the variables studied and
no significant differences were identified in the variables
involved in the version success rate, i.e., parity, breech vari-
ety, placental location w4, 7, 8, 10, 11x.
Several studies have shown the efficacy of atosiban in the
treatment of preterm labor w1, 5, 6, 21x but only one has
studied it in the ECV procedure w12x. The study concludes
that there are no significant differences between atosiban and
ritodrine, although the results, as suggested by the authors,
should be interpreted with caution due to the study design
and sample size: a retrospective study in which the two
cohorts have been selected in different years, and the initial
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sample size was limited, 21 in the atosiban cohort and 17 in
the ritodrine cohort, with a high rate of spontaneous versions
before the maneuver (11 cases).
According to our protocol, ritodrine is administered via
continuous 200 mg infusion pump starting 30 min before the
version is practiced and is maintained during the procedure,
whereas atosiban is administered in a single bolus dose of
0.9 mL only 2 min before the procedure. Several studies have
examined the acute tocolytic effect of atosiban, with the
same bolus dose, namely in intralabor scenarios in gestations
at term w9, 13, 18x. These studies conclude that both drugs
have the same acute tocolytic potential, although betami-
metics have a higher rate of side effects.
In view of our results, atosiban success rate (31.4%) is
significantly lower than ritodrine (56.8%). Given this differ-
ence in the success rate, the rate of cesarean sections in the
atosiban cohort (57.6%) was significantly higher than that
of ritodrine (36.4%). According to the data published suc-
cess rates of atosiban are very similar to those described for
groups in which no tocolysis is performed w19, 20, 24x, sug-
gesting that the desired tocolytic effect has not been
produced.
Beta-adrenergic agonists, like ritodrine, stimulate the adre-
nergic receptors involved in the autonomous regulation of
uterine contraction. Thus, they activate adenylate cyclase by
increasing cyclic adenosine mono-phosphate concentration,
which leads to a reduction in the amount of calcium avail-
able, together with an inhibition of the myosin light-chain
kinase. Antagonists of oxytocin, like atosiban, act as a selec-
tive competitive inhibitor of oxytocin receptors involved in
the hormonal regulation of uterine contraction. Inhibiting the
activation of the receptor means that there is no activation
of phosphatidinositol, which stimulates calcium contraction
via secondary messengers and thus, the activation of the
myosin light-chain kinase w15x. Although the end effect of
both drugs is the same, the mechanism of action is different.
Thus, the potential of atosiban in ECV will be very low,
which would explain why success rates are very similar to
those obtained for those groups in which the version was
performed without tocolysis.
Several studies confirmed that atosiban has a good safety
profile whereas clinical signs of cardiovascular distress are
relatively common in women treated with ritodrine w14, 22x.
In our study, all of the adverse events were observed in the
ritodrine group (4.23%), but none were associated with
adverse perinatal outcomes, and clinical signs of cardiovas-
cular distress were only in one woman (0.84%).
Finally, the number of patients in which a version should
be performed in order to avoid a cesarean section is almost
three times higher with atosiban than with ritodrine. How-
ever, the numbers needed to treat (NNT) have been calcu-
lated in a hospital in which vaginal deliveries with breech
presentation are done, which is why the NNT to avoid a
cesarean is higher than in centers in which a cesarean is
performed in most breech presentations.
In conclusion, ritodrine seems better than atosiban as a
tocolytic agent in ECVs. Atosiban is an effective tocolytic
agent that can be used in patients with contraindications or
at high risk for ritodrine, although its beneficial tocolytic
effect on the version should be examined in a randomized
trials.
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